All Eyes on InspireMD’s Q3 Report as CGuard Prime Launch Takes Center Stage

InspireMD is scheduled to announce its third-quarter 2025 financial results on November 4, before the market opens. The investment community is keenly awaiting this report, as it promises to deliver the first concrete data on the U.S. commercial rollout of the company's CGuard Prime Embolic Prevention System (EPS).

Financial Backdrop and Strategic Positioning

The upcoming earnings release follows a mixed second quarter. While InspireMD posted a modest 2.3% revenue increase to $1.78 million, it was overshadowed by a substantial net loss of $13.15 million, a result that fell short of market expectations. Despite these disappointing figures, the quarter was marked by significant strategic victories that have fortified the company's position. The FDA approval for CGuard Prime, coupled with a successful $58 million capital raise, has provided essential resources for the crucial U.S. market entry.

The Pivotal U.S. Commercial Launch

Should investors sell immediately? Or is it worth buying InspireMD?

The core narrative for InspireMD now revolves entirely around the market performance of CGuard Prime. The commercial launch in the United States commenced on July 9, following the regulatory green light from the FDA at the end of June. This medical device is designed to minimize the risk of embolism during procedures through its proprietary mesh coating, offering a minimally invasive option for stroke prevention.

Future Catalysts and Investor Focus

Market participants will be scrutinizing the report and the accompanying conference call, scheduled for 2:30 PM CET today, for clear indicators of CGuard Prime's early market acceptance. Investors are also anticipating revised revenue guidance after management previously signaled expectations for sequential growth in Q3 and beyond. Additional milestones on the horizon include progress updates on the C-GUARDIANS II study and development timelines for the SwitchGuard TCAR approval, which are projected for 2026 and 2027, respectively. The insights provided on the call will be critical for assessing the operational execution and commercial trajectory of the CGuard Prime launch.